Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Deal Watch: Lilly, AbCellera Partner To Attempt Rapid COVID-19 Antibody Development

Executive Summary

Partnership will combine AbCellera’s screening of antibodies to the virus with Lilly’s development, commercial capabilities. Vir adds Biogen tie-up to its ongoing coronavirus efforts.

You may also be interested in...



Lilly Claims Proof Of Concept For Neutralizing Antibodies In COVID-19 Therapy

Analysts called the interim data from a Phase II study of LY-CoV555 mixed, but Lilly insists that it has demonstrated a therapeutic role for neutralizing antibodies in fighting the novel coronavirus.

Lilly Saw Pandemic-Related Benefits In Q1, Expects Headwinds Long Term

The pharma saw a $250m revenue increase due to inventory stockpiling and early prescription renewals, but its therapies outside cancer and diabetes may suffer in the coming quarters due to COVID-19.

Vir Advances HBV, Flu Programs While Focused On COVID-19

Vir began pursuing immunological approaches to infectious diseases three years before its COVID-19 work. Its hepatitis B, flu and HIV clinical trials are delayed about six months due to coronavirus-related issues.

Related Content

Topics

Related Companies

Related Deals

UsernamePublicRestriction

Register

MT125529

Ask The Analyst

Please Note: Click here for more information on the Ask the Analyst service.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel